Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000712397 | SCV000618640 | likely benign | not provided | 2018-05-21 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001079382 | SCV000763130 | likely benign | Nemaline myopathy 2 | 2024-12-24 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000712397 | SCV000842878 | uncertain significance | not provided | 2018-07-20 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000712397 | SCV003810143 | uncertain significance | not provided | 2019-08-07 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001079382 | SCV001454965 | uncertain significance | Nemaline myopathy 2 | 2020-01-17 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004553142 | SCV004770746 | likely benign | NEB-related disorder | 2020-06-08 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |